Colorectal Carcinoma, Mesothelioma, Ovarian Carcinoma, Pseudomyxoma Peritonei
Conditions
Keywords
Peritoneal carcinomatosis, Peritoneal surface malignancy, Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy, CRS, HIPEC, Prognostic biomarker, Predictive biomarker
Brief summary
The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through animal models to explore different treatment strategies for peritoneal surface malignancies (PSM).
Detailed description
The handling of patients with PSM involves multimodal and multidisciplinary treatment strategies such as CRS, the removal of all macroscopically detectable tumor, and HIPEC, instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease. The treatment is challenging and complex and associated with significant morbidity. Only patients with limited disease will benefit from the treatment, and better methods for patient selection are needed. The project group has a unique opportunity to address key questions because of acquired experience, an exceptional biobank and institutional database and novel animal models established at the Norwegian Radium Hospital.
Interventions
OTHERObservational study.
Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor. HIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease.
Sponsors
The Research Council of Norway
Oslo University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age \> 18 years * confirmed diagnosis of peritoneal surface malignancy * candidate for CRS-HIPEC * written informed consent
Exclusion criteria
* none Approximately 80 patients per year will be eligible for inclusion, as this is the number of patients that annually receive surgical treatment for PSM.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | 5 years | Time from surgery until death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival (DFS) | 5 years | Time from surgery until disease recurrence or death |
Countries
Norway
Contacts
Primary ContactKjersti Flatmark, MD PhD
Backup ContactAnnette Torgunrud Kristensen, PhD
Outcome results
None listed